Scholarlink

Background <p>With the individual reduction of radiation field sizes and positron-emission tomography (PET)-guided radiotherapy (RT), benefit-adapted individualization of RT has become standard in the setting of combined modality therapy for Hodgkin lymphoma (HL). In recent years, the concept of combined benefit- and risk-adapted individualization has also been developed.</p> Purpose <p>This article aims to present the various concepts of individualized RT for HL.</p> Materials and methods <p>A&#xa0;review of the individualization of RT for HL was performed using a&#xa0;literature search in PubMed.</p> Results <p>Due to the young patient population and the good prognosis, reducing the long-term toxicity of HL treatment is particularly relevant. The long-term toxicity of RT has already been significantly reduced by decreasing the size of the radiation fields to involved-site radiotherapy (ISRT) and establishing PET-guided RT. In contrast to this established benefit-adapted individualization of RT, combined benefit- and risk-adapted individualization also takes into account the individual risk of long-term toxicities, so that affected lymph node areas may spared irradiation in order to avoid long-term toxicities. Models that enable this assessment in a&#xa0;preclinical context already exist. However, they have not yet been validated, which precludes their use in everyday clinical practice.</p> Conclusion <p>There are promising approaches to the combined benefit- and risk-adapted individualization of radiation therapy for Hodgkin lymphoma, but these cannot yet be used in routine clinical practice due to a&#xa0;lack of validation. However, they will become more relevant in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Individualisierte Strahlentherapie des Hodgkin-Lymphoms

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Johannes Rosenbrock,
  • Simone Ferdinandus,
  • Emmanouil Fokas,
  • Christian Baues

摘要

Background

With the individual reduction of radiation field sizes and positron-emission tomography (PET)-guided radiotherapy (RT), benefit-adapted individualization of RT has become standard in the setting of combined modality therapy for Hodgkin lymphoma (HL). In recent years, the concept of combined benefit- and risk-adapted individualization has also been developed.

Purpose

This article aims to present the various concepts of individualized RT for HL.

Materials and methods

A review of the individualization of RT for HL was performed using a literature search in PubMed.

Results

Due to the young patient population and the good prognosis, reducing the long-term toxicity of HL treatment is particularly relevant. The long-term toxicity of RT has already been significantly reduced by decreasing the size of the radiation fields to involved-site radiotherapy (ISRT) and establishing PET-guided RT. In contrast to this established benefit-adapted individualization of RT, combined benefit- and risk-adapted individualization also takes into account the individual risk of long-term toxicities, so that affected lymph node areas may spared irradiation in order to avoid long-term toxicities. Models that enable this assessment in a preclinical context already exist. However, they have not yet been validated, which precludes their use in everyday clinical practice.

Conclusion

There are promising approaches to the combined benefit- and risk-adapted individualization of radiation therapy for Hodgkin lymphoma, but these cannot yet be used in routine clinical practice due to a lack of validation. However, they will become more relevant in the future.